In vivo delivery of synthetic DNA-encoded antibodies induces broad HIV-1-neutralizing activity.

ABSTRACT: Interventions to prevent HIV-1 infection and alternative tools in HIV cure therapy remain pressing goals. Recently, numerous broadly neutralizing HIV-1 monoclonal antibodies (bNAbs) have been developed that possess the characteristics necessary for potential prophylactic or therapeutic approaches. However, formulation complexities, especially for multiantibody deliveries, long infusion times, and production issues could limit the use of these bNAbs when deployed, globally affecting their potential application. Here, we describe an approach utilizing synthetic DNA-encoded monoclonal antibodies (dmAbs) for direct in vivo production of prespecified neutralizing activity. We designed 16 different bNAbs as dmAb cassettes and studied their activity in small and large animals. Sera from animals a

SUBMITTER: Wise MC 

PROVIDER: S-EPMC6994112 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature